An independent two-stage DCF analysis by a frontier AI model.
" data-astro-cid-kqs4eajd> Medtronic has experienced slow-to-moderate top-line growth. While new product cycles (like Hugo robotics and diabetes care) offer catalysts, the law of large numbers and competitive pressures keep sustainable medium-term growth in the mid-single digits.
" data-astro-cid-kqs4eajd> 10Y Treasury: 4.18%. As a defensive healthcare stock with highly predictable cash flows and low macroeconomic cyclicality, Medtronic commands a lower cost of capital than high-growth tech or cyclical industrials. 8% represents a solid required return.
" data-astro-cid-kqs4eajd> A long-term growth rate of 2.5% reflects perpetual healthcare spending increases, inflation, and pricing power. It is intentionally conservative, ensuring we do not over-rely on terminal value inflation to justify the current price.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 1.5% | $59.17 | $35.50 | $25.36 | $19.72 | $16.14 |
| 2.0% | $88.75 | $44.38 | $29.58 | $22.19 | $17.75 |
| 2.5% | $177.50 | $59.17 | $35.50 | $25.36 | $19.72 |
| 3.0% | $35.50 | $88.75 | $44.38 | $29.58 | $22.19 |
| 3.5% | $35.50 | $177.50 | $59.17 | $35.50 | $25.36 |
■ Undervalued vs current price ■ Overvalued vs current price
Medtronic plc is a massive global medical device company operating in over 150 countries. Despite recent execution challenges, it generates strong revenue growth of 8.7% and impressive operating margins of 20%. The company produces over $4B in free cash flow, supporting a solid 3.27% dividend yield. Strategic restructuring and a renewed focus on innovation are beginning to show promise, making it a compelling, albeit transitioning, prospect.
Medtronic's momentum is mixed. While core segments remain stable, growth has lagged some more focused peers, prompting a strategic realignment.
The economic moat remains wide, supported by deep relationships with healthcare providers, high switching costs for surgeons, and a vast intellectual property portfolio.
Sentiment is cautiously optimistic, as investors look for consistent execution of the company's turnaround strategy and the successful launch of pipeline products.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.